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The International Society for Stem Cell Research (ISSCR) task force that developed new Guidelines for the
Clinical Translation of Stem Cells discusses core principles that should guide the responsible transition of
basic stem cell research into appropriate clinical applications.Rapid advances in all forms of stem cell research have raised the
hopes of patients that they may one day receive new stem-cell-
based therapies to relieve their disabilities or even cure them of
their disease. While stem-cell-based therapies are the clinical
standard of care for a few conditions, such as hematopoietic
stem cell transplants for leukemia and epithelial-stem-cell-
based treatments for burns and corneal disorders, the general
public may not fully understand how many years of preclinical
and clinical research will be required to bring novel stem-cell-
based therapies to fruition. Unfortunately, there are some clinics
around the world already exploiting patients’ hopes by purport-
ing to offer effective stem cell therapies for seriously ill patients,
typically for large sums of money, but without credible scientificrationale, transparency, oversight, or patient protections (Lau
et al., 2008).
The ISSCR believes that administering unproven stem cell
interventions outside a carefully regulated clinical trial puts indi-
vidual patients at risk and also jeopardizes the legitimate prog-
ress of translational stem cell research. To address this concern,
the ISSCR convened an international task force (Daley et al.,
2008) to develop Guidelines for the Clinical Translation of Stem
Cells (available at http://www.isscr.org/clinical_trans), which
provides a framework for the responsible and timely develop-
ment of clinically useful stem-cell-based therapies. Due to the
wide variety of possible stem-cell-based treatments that may
be pursued, the ISSCR guidelines offer a set of generalCell Stem Cell 3, December 4, 2008 ª2008 ISSCR 607
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with overseeing research and clinical practice to assist their
thinking about individual cases. The ISSCR guidelines pay
special attention to issues that are stem cell specific while reiter-
ating international standards of biomedical research, including
independent peer review and oversight and strict adherence
to high standards of voluntary informed consent. Below we
summarize the fundamental professional and ethical principles
underlying the recommendations set forth in the guidelines.
Major Principles
Independent Review and Oversight
Although biomedical research is already subject to peer review,
regulation, and oversight, the ISSCR guidelines stress the impor-
tance of subject-specific expertise during review of translational
research. Given the novelty and unpredictability of early stem-
cell-based clinical trials, it is of utmost importance that individuals
with stem-cell-specific expertise be involved in the scientific and
ethical review at each step along the translational research pro-
cess. Individuals with stem-cell-specific expertise are best able
to assist investigators and human research review committees
to assess the scientific underpinnings of the clinical trial protocol;
the in vitro and in vivo preclinical studies that form the basis for
proceeding to the clinical study; and the risks of abnormal product
function, proliferation, and/or tumor development. The guidelines
call on committees responsible for the oversight of human
subjects research to draw on stem-cell-specific expertise in the
evaluation of clinical protocols involving (1) products from human
embryonic or other pluripotent stem cells; (2) novel applications of
fetal or somatic (adult) stem cells; and (3) hematopoietic and other
stem cells used for applications outside established standards of
care. The ISSCR guidelines do not call for stem cell research
oversight (SCRO) committees, established to review laboratory
studies involving human embryonic stem cells, to conduct a sep-
arate review of clinical protocols, although some members of
these bodies may be used as consultants to the review commit-
tees responsible for review and oversight of clinical research. In
research locales without stem cell expertise, the ISSCR will help
identify appropriate domain experts to assist in the human
subjects review process.
The success of stem-cell-based therapies begins with the
adoption of cell processing and manufacturing methods that
promote maximal quality and safety of the cells to be used.
The ISSCR guidelines emphasize the importance of accepted
principles and practices of quality control conducted under
expert and independent oversight at a level that is proportional
to the degree of risk raised by the particular cell product and
its intended use. The variety of cell types and sources, modes
of processing, and biological variability creates significant chal-
lenges in the validation of cell products (A¨hrlund-Richter et al.,
2009). Systematic assessment of integrity and potency of cell
products is essential to minimizing risk to patients. The task force
recognized that the establishment of assays and surrogate
markers will be refined over time and recommends that scien-
tists and regulators work together to develop common reference
standards, not only to ensure cell quality and safety, but also to
facilitate comparisons across studies.
Preclinical studies are used to provide evidence of safety and
to establish proof of principle for therapeutic effect. The ISSCR608 Cell Stem Cell 3, December 4, 2008 ª2008 ISSCRguidelines underscore the importance of independent peer
review in assessing preclinical data to ensure that clinical strat-
egies are based on sound scientific rationale and adequate
evidence for safety and efficacy before advancing to human clin-
ical studies. Sufficient preclinical studies in relevant animal
models are necessary to make proposed stem-cell-based clini-
cal research ethical, unless approved, controlled, and conclu-
sive human studies are already available with the same cell
source and route of delivery. Rigorous preclinical testing in
animal models—whenever possible for the clinical condition
and the tissue physiology being studied—is especially important
for stem-cell-based approaches because stem cells can act
through multiple mechanisms, and because it is difficult to
predict behavior in an animal from cell culture studies alone.
Additional burden to demonstrate safety and efficacy falls on
preclinical animal studies where cells have undergone extensive
ex vivo manipulation and/or when the cells have been derived
from pluripotent stem cells. Investigators may need to develop
preclinical studies in both small and large animal models. The
ISSCR guidelines acknowledge, however, the limitations of
animal experiments in predicting how transplanted cells will
behave in the human due to the context-dependent nature of
cell behavior and the unique facets of human physiology. Thus,
frequent interaction between preclinical and clinical investiga-
tors is strongly recommended to address unforeseen safety con-
cerns, and a clear plan to assess the risks of tumorigenicity and
any other adverse effects should be developed and reviewed
prior to approval for clinical research.
Voluntary Informed Consent
As established in widely accepted international ethics docu-
ments pertaining to research with human subjects, voluntary
informed consent is a cornerstone of ethical clinical research.
The ISSCR guidelines recommend that special emphasis be
placed on the unique risks of stem-cell-based clinical research
during the informed consent process. These risks include sensi-
tivities surrounding the source of cellular products, tumor forma-
tion, immunological reactions, unexpected behavior of the cells,
and unknown long-term health effects. Research volunteers
must be educated about the realistic potential for therapeutic
benefit as they may have recourse to reasonable therapeutic
alternatives and because they may harbor misconceptions
about the potential for therapeutic efficacy. Moreover, the ISSCR
guidelines recommend that research subjects’ comprehension
of relevant information—especially of the risks and uncer-
tainties—be evaluated at the time of obtaining consent. For
patients contemplating participation in stem-cell-based clinical
research, the ISSCR provides information for patients in the
appendices of the guidelines to assist their decision making.
Patient Monitoring and Adverse-Event Reporting
Risks to future research participants may be further minimized
through careful patient-subject monitoring and timely adverse-
event reporting. The ISSCR guidelines maintain that the welfare
of research participants is of utmost importance and that their
health must be carefully monitored throughout the duration of
the stem-cell-based clinical trial. Given the unknowns of stem-
cell-based clinical research, a data monitoring plan is required
for all clinical studies, and aggregate updates should be
provided to peer review committees on demand, based on
adverse-event reporting and ongoing statistical analyses.
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positive results, negative results, and adverse events and thus
promote transparency, to prevent others from being subjected
to unnecessary risk in future clinical research and to ensure the
development of clinically effective and competitive stem-cell-
based therapies.
Medical Innovation
Another key issue addressed is whether it is ever permissible for
clinicians to attempt medically innovative care for their patients’
benefit using stem-cell-derived cellular products outside the
context of a formal clinical trial. The ISSCR guidelines acknowl-
edge that there may be exceptional circumstances that allow
clinicians to attempt medically innovative care in a very small
number of seriously ill patients, subject to stringent oversight
criteria. These criteria include independent peer review of the
proposed innovative procedure and its scientific rationale, insti-
tutional accountability, rigorous informed consent and close pa-
tient monitoring, transparency, timely adverse-event reporting,
and a commitment by clinician-scientists to move to a formal
clinical trial in a timely manner after experience with at most
a few patients. The task force believes that holding some current
stem cell clinics to the standards outlined in the guidelines would
identify significant shortcomings and call into question the legit-
imacy of their purported attempts at providing ‘‘innovative care’’
to their patients.
Social Justice and Other Aspirational Goals
The road to broad clinical translation of stem cells is likely to be
long and fraught with challenges. As stem-cell-based clinical
research activities are initiated and their numbers increase
over time, it is imperative that principles of social justice be con-
sidered. A major justification for the public support of stem cell
research is the promise of substantial social benefit, and there-
fore the benefits of research must be justly shared. The ISSCR
guidelines recommend that translational stem cell investigators
and regulatory bodies attend to issues of justice that are tradi-
tionally brought to bear in clinical research, including the fairness
of subject selection and whether the participants will receive the
benefits of research discoveries and therapies. Explicit attention
paid to social justice, together with the other core principles
articulated in the ISSCR guidelines, will go far in advancing the
promise of stem cell research on both ethical and scientific
grounds.Looking Ahead
Around the world, new discoveries with clinical implications are
continuously made in basic stem cell research, and stem-cell-
based approaches are advancing rapidly toward application in
patients. With these advancements comes the responsibility to
attend to the safety and welfare of patients and research sub-
jects at all times. The ISSCR is committed to ongoing review
and revision of the Guidelines for the Clinical Translation of
Stem Cells to keep pace with new developments in the field
and to protect the interests of individuals and communities.
The ISSCR guidelines should continue to promote the responsi-
ble translation of stem cell research into clinically competitive
and effective, novel stem-cell-based therapies for various
human diseases.
ACKNOWLEDGMENTS
The ISSCRGuidelines for theClinical Translation of StemCellswere created by
a multinational, multidisciplinary group of researchers, clinicians, ethicists, and
regulatory officials from 13 countries. The ISSCR wishes to acknowledge the
financial support of the EUROCORES Programme EuroSTELLS, a European
Science Foundation (ESF) initiative, supported by the European Commission,
Sixth Framework Programme, under contract number ERAS-CT-2003-98409.
Research funding is provided by participating national organizations.
EuroSTELLS is managed by the European Medical Research Councils
(EMRC) at the ESF. The ISSCR also thanks the Alzheimer’s Research Founda-
tion, The Ellison Medical Foundation, and the Juvenile Diabetes Research
Foundation for their generous financial support of the task force. The task force
wishes to acknowledge helpful consultation from representatives of the U.S.
Food and Drug Administration. D.R.M. is an employee, corporate officer,
and shareholder of PerkinElmer Inc., which sells instruments, reagents, soft-
ware, and services to the pharmaceutical, biotechnology, and medical device
industries. PerkinElmer Inc. also has a business that provides services for
umbilical cord blood banking, neonatal screening, and prenatal screening.
M.R. is an employee of Invitrogen Inc., which provides goods and services
to the research industry, including the cell therapy industry.
REFERENCES
A¨hrlund-Richter, L., De Luca, M., Marshak, D.R., Munsie, M., Veiga, A., and
Rao, M. (2009). Cell Stem Cell 4, in press. Published online December 4, 2008.
Daley, G.Q., Hyun, I., and Lindvall, O. (2008). Cell Stem Cell 2, 139–140.
Lau, D., Ogbogu, U., Taylor, B., Stafinski, T., Menon, D., and Caulfield, T.
(2008). Cell Stem Cell 3, this issue, 591–594.Cell Stem Cell 3, December 4, 2008 ª2008 ISSCR 609
